Dawnzera (donidalorsen)

Approved for DAWNZERA is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.. Donidalorsen is an ASO-GalNAc conjugate that causes RNase H1-mediated degradation of prekallikrein (PKK) mRNA. Side effects, costs, interactions, manufacturer, and generic alternatives sourced from FDA labels, openFDA FAERS, and CMS…

Loading full data from Know Your Drugs Institute…